From the Chair Magellan Continues to progress its operational and strategic plans. With a focus on a successful laboratory licensing process for the TGA, publication of the results of the Phase 1/2 trial, preparation for the Phase 3 trial in 2025 and ongoing planning for eventual manufacture of cells for our trial and others our […]
Magellan are pleased to announce the results of our Phase 1/2 allogenic trial. The research findings are published in Osteoarthritis and Cartilage Open the open-access journal of Osteoarthritis Research Society International (OARSI), which publishes the evidence-based, international consensus guidelines on osteoarthritis management.
Australian Health Minister announced a $7 million grant to Magellan Stem Cells – read more here
Should you want further information regarding our results or media release please email info@magellanstemcells.com.au or call 03 9270 8080.
